AbbVie opened a 480,000-sf biomedical research center in South San Francisco in April of 2022. Offering state-of-the-art laboratories and collaborative workspaces, the leased facility will accelerate the discovery and commercialization of new cancer therapeutics. As the anchor tenant for the Gateway of Pacific’s first phase of construction, AbbVie occupies 11 contiguous floors in the 12-story structure.
EMD Serono completed construction in March of 2022 on the $70 million Horizon Building in Billerica, Mass. Designed by PM Group, the 149,000-sf structure provides collaborative research environments to accelerate the creation of specialty pharmaceuticals. The mixed-use R&D facility includes approximately 30,000 sf of flexible wet lab space featuring reconfigurable benches and overhead service panels with plug-and-play connectivity.
HYM Investment Group began construction in March of 2022 on a $280 million biomanufacturing hub in Revere, Mass. Designed by Elkus Manfredi Architects, the six-story life sciences facility will offer leasable research environments for biomedical and pharmaceutical companies. Complemented by retail and dining amenities, the structure will feature two double-height floors for GMP production and manufacturing activities.
Wake Technical Community College opened the $47 million Lilly Science and Technology Center in Morrisville in March of 2022. Designed by O'Brien Atkins Associates, the 66,000-sf facility features smart learning environments for programs in biotechnology and business analytics. Housing a biochemistry lab for training in raw materials testing and in-process sampling, the three-story building also provides a microbiology lab where students can learn best practices for gene therapy, genetics, cell culture, DNA manipulation, and industrial microbiology.
Amgen broke ground in March of 2022 on a $550 million biomanufacturing center in Holly Springs, N.C. Accommodating the company's FleXBatch platform, the project will integrate traditional methods for drug substance production with single-use bioprocessing technologies to create a hybrid facility with unrivaled operational efficiencies. The next-generation plant will manufacture advanced therapeutics for the treatment of cardiovascular disease, cancer, osteoporosis, inflammation, and other conditions.
Bristol Myers Squibb is partnering with Alexandria Real Estate Equities to create a 427,000-rsf R&D center in San Diego. Located in the Alexandria Point development, the leased facility will provide core labs for the creation of advanced biopharmaceutical therapies. Housing nearly 600 researchers and staff members, the collaborative building will consolidate employees from several regional campuses into a flexible working ecosystem for discovery and innovation.
Vermeulens has released its market outlook report for the fourth quarter of 2021. Key points include:
Eli Lilly & Company is investing approximately $700 million to create the Institute for Genetic Medicine in Boston. Located in the Seaport district, the leased facility will provide 334,000 rsf of leading-edge research space for the discovery of innovative RNA and DNA-based therapies. The project will also include a shared R&D center with dedicated and configurable lab environments to enable biotech start-ups to collaborate with Lilly scientists.
Piramal Pharma Solutions broke ground in February of 2022 on a £45 million antibody drug conjugate (ADC) facility in Grangemouth, Scotland. Accommodating both manufacturing and aseptic fill/finish operations, the structure will provide additional capacity for the creation of targeted cancer treatments and other innovative therapies. Representing an expansion of Piramal's existing ADC campus, the project is being delivered by Merit using its FlexiPOD V4.0 platform.
Vibalogics completed construction in December of 2021 on a $150 million virotherapy facility in Boxborough, Mass. Sited on 145 acres, the next-generation manufacturing plant supports commercial production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products. The highly flexible structure incorporates 2,000-liter bioreactors, multiple cGMP production suites, offices, warehouse space, and labs for research, development, and quality control.
Leggat McCall Properties and DLJ Real Estate Capital Partners are planning to construct a 353,000-sf life sciences facility in Somerville, Mass. Offering 346,000 sf of leading-edge lab space for biomedical and pharmaceutical tenants, the 11-story structure will include 7,000 sf of retail space and below-grade parking for 242 cars.
Phase 3 Real Estate Partners and Bain Capital are constructing the Genesis Marina life sciences campus in Brisbane, Calif. Providing over 570,000 rsf of Class A laboratory and office space, the three-building complex will offer floor plates of up to 42,000 sf serviced by robust MEP infrastructure.
Pfizer opened a $68.5 million clinical manufacturing facility in December of 2021 in Durham. Accommodating the company's BioTherapeutics Pharmaceutical Sciences division, the 85,500-sf project will support the creation of gene therapies for the treatment of hemophilia A, hemophilia B, Duchenne muscular dystrophy, and other diseases. Leveraging single-use bioreactors to enable scalable expansion over time, the structure provides multiple drug substance suites, analytical and microbiology labs, and areas for manufacturing and filling.
Washington University School of Medicine will break ground in spring of 2022 on a $150 million vertical expansion of the Steven & Susan Lipstein BJC Institute of Health in St. Louis. Designed by Lawrence Group to promote collaboration and discovery, the six-story, 160,000-sf addition will provide 103,000 sf of biomedical research space and a 7,900-sf BSL-3 laboratory for the study of infectious diseases such as SARS-CoV-2 and tuberculosis.
Genentech has agreed to a whole-building lease for a 229,000-sf life sciences facility at Gateway Commons in South San Francisco. Developed by Alexandria Real Estate Equities and Boston Properties, 751 Gateway will provide leading-edge lab and office environments for biomedical and pharmaceutical research. Featuring best-in-class amenities, the collaborative structure represents the first phase of a vibrant biomedical campus. Construction is ongoing with initial occupancy expected in early 2024.
